11 May 2026
Artificial intelligence is no longer a future concept in the pharmaceutical sector. It is already reshaping how new drugs are discovered, designed, tested and manufactured — and that shift is creating major opportunities for businesses working in life sciences, biotech and medical innovation.
For pharmaceutical companies and venture-backed startups alike, the appeal is obvious. Bringing a new drug to market is expensive, slow and risky. It can take more than a decade and cost upwards of $1 billion to move from early discovery to an approved therapy. That means any technology capable of shortening timelines, reducing trial-and-error and improving the odds of success has enormous value.
AI is increasingly being seen as that technology.
From “undruggable” to discoverable
One of the most exciting promises of AI in pharma is its ability to help researchers tackle biological targets that were once considered too difficult to treat. In simple terms, AI can help scientists find patterns, model molecules and predict outcomes faster than traditional methods alone.
That matters in a sector where small gains in speed can translate into huge commercial and clinical advantages.
Roche recently said its AI tools helped researchers design a specialised oncology molecule 25% faster — and with a structure that may not have been achievable through conventional methods. In another cancer program now progressing into human trials, AI was used to predict and reduce the risk that the therapy would trigger an unwanted immune response.
This is where AI becomes more than a productivity tool. It becomes part of the scientific engine itself.
AI is spreading across the entire pharma value chain
What is changing now is the scope.
AI is no longer being treated as something useful in only one corner of the drug development process. It is being embedded across research, development, manufacturing and commercial strategy all at once.
That includes:
-
identifying promising drug targets
-
designing and refining molecules
-
predicting safety and immunogenicity risks
-
improving clinical trial design and recruitment
-
streamlining manufacturing and process optimisation
-
accelerating decision-making across R&D pipelines
Large pharmaceutical companies are also combining internal AI capability with strategic partnerships. Roche, for example, struck a deal with startup Manifold Bio to explore AI-enabled ways of delivering medicines to the brain. The deal reportedly included substantial upfront payment and milestone-based upside running into the billions.
That tells you something important: this is not just experimentation. It is investment at scale.
Why this matters for patents
As AI becomes more deeply embedded in pharmaceutical innovation, the patent questions become more important too.
In pharma, timing is everything. Patent life is finite, and every year spent in research and clinical development eats into the period in which an innovator can commercially benefit from an invention. If AI can help shorten the path to market, it can materially improve the commercial value of a patented drug or platform.
But speed is only part of the story.
AI may also generate new forms of patentable value across the innovation chain, including:
-
novel therapeutic compounds
-
engineered molecular structures
-
delivery systems
-
manufacturing methods
-
formulation improvements
-
AI-enabled drug discovery platforms
For many businesses, the real opportunity is not just the end product, but the surrounding IP position. That could include patents, trade secrets, licensing strategies, data-related know-how and carefully managed freedom-to-operate.
In other words, if AI is helping create better science faster, IP is what helps turn that scientific progress into a defendable commercial asset.
The winners may be the ones who build AI and IP strategy together
The companies likely to benefit most from this shift will not be the ones simply using AI tools. They will be the ones thinking early about how to protect what those tools help create.
That means asking the right questions from the outset:
-
What in this workflow is actually protectable?
-
Is the value sitting in the molecule, the method, the platform, or all three?
-
Should parts of the innovation be patented, or kept confidential?
-
Are there freedom-to-operate risks emerging as AI accelerates R&D?
-
How can IP strategy keep pace with faster scientific cycles?
These are not questions to leave until the end of development.
AI is moving fast — and so should protection strategy
The direction of travel is clear. AI is becoming embedded throughout pharma R&D, and the commercial consequences will be significant. Faster discovery, smarter development and more efficient manufacturing all create value — but capturing that value requires a clear IP strategy.
For businesses operating in biotech, pharmaceuticals, medtech or AI-enabled life sciences, this is the time to think not only about what can be built, but what can be protected.
At IP Solved, we help innovative businesses identify, protect and strengthen the IP behind emerging technologies — including inventions shaped by AI-driven R&D. If your business is developing new therapies, platforms, formulations or enabling technologies, talk to our team about how to build an IP strategy that supports both innovation and commercial growth.
